FY2024 Earnings Estimate for VRDN Issued By Leerink Partnrs

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Investment analysts at Leerink Partnrs cut their FY2024 earnings per share estimates for Viridian Therapeutics in a research note issued on Tuesday, November 12th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of ($3.85) for the year, down from their previous estimate of ($3.83). The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($3.94) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q4 2024 earnings at ($0.88) EPS, FY2025 earnings at ($3.71) EPS, FY2026 earnings at ($3.05) EPS, FY2027 earnings at ($1.47) EPS and FY2028 earnings at $1.26 EPS.

Other analysts have also issued reports about the company. The Goldman Sachs Group raised their price objective on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, September 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Oppenheimer reaffirmed an “outperform” rating and issued a $28.00 price target (down from $31.00) on shares of Viridian Therapeutics in a research note on Monday, August 12th. BTIG Research lifted their price target on Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a research note on Wednesday. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, Viridian Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $36.33.

Viridian Therapeutics Stock Down 3.7 %

Shares of VRDN opened at $21.64 on Friday. The company has a current ratio of 15.82, a quick ratio of 15.82 and a debt-to-equity ratio of 0.05. Viridian Therapeutics has a 12 month low of $11.40 and a 12 month high of $27.20. The stock’s 50 day moving average is $22.35 and its two-hundred day moving average is $16.89. The firm has a market cap of $1.71 billion, a P/E ratio of -5.02 and a beta of 1.10.

Insider Buying and Selling

In other Viridian Therapeutics news, COO Thomas W. Beetham bought 5,000 shares of Viridian Therapeutics stock in a transaction on Friday, September 27th. The shares were bought at an average price of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the transaction, the chief operating officer now directly owns 6,000 shares of the company’s stock, valued at $140,460. This trade represents a 500.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Stephen F. Mahoney bought 21,400 shares of Viridian Therapeutics stock in a transaction on Friday, September 27th. The stock was acquired at an average price of $23.33 per share, for a total transaction of $499,262.00. Following the transaction, the chief executive officer now directly owns 21,400 shares of the company’s stock, valued at approximately $499,262. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 1,626,400 shares of company stock worth $30,616,312. 0.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Viridian Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC raised its position in Viridian Therapeutics by 16.8% in the third quarter. FMR LLC now owns 11,183,478 shares of the company’s stock valued at $254,424,000 after purchasing an additional 1,610,130 shares during the period. Maverick Capital Ltd. raised its holdings in shares of Viridian Therapeutics by 22.9% in the 2nd quarter. Maverick Capital Ltd. now owns 3,307,945 shares of the company’s stock valued at $43,036,000 after buying an additional 615,531 shares during the period. Vanguard Group Inc. raised its holdings in shares of Viridian Therapeutics by 7.8% in the 1st quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after buying an additional 233,331 shares during the period. Novo Holdings A S raised its holdings in shares of Viridian Therapeutics by 19.3% in the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock valued at $54,259,000 after buying an additional 385,000 shares during the period. Finally, Great Point Partners LLC raised its holdings in shares of Viridian Therapeutics by 50.0% in the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock valued at $17,062,000 after buying an additional 250,000 shares during the period.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.